Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Rezlidhia (olutasidenib) is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
Lead Product(s): Olutasidenib
Therapeutic Area: Oncology Product Name: Rezlidhia
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Rigel Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 13, 2022